December 6, 2016 / 7:11 AM / 8 months ago

BRIEF-Asit Biotech presents ASIT+ benefits in treating grass pollen rhinitis

1 Min Read

Dec 6(Reuters) - Asit Biotech SA :

* Reported on Monday ASIT+ technology's benefits in treating grass pollen rhinitis presented during a scientific session at Medical Research Council & Asthma UK Centre in London

* gp-ASIT+ is the Company`s most advanced drug candidate

* Its clinical efficacy is being investigated in a Phase III clinical trial in Europe

* The results of this study should be available during the first quarter of 2017 Source text for Eikon: Further company coverage:

Gdynia Newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below